Goldman Sachs’s Adient ADNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-110
Closed -$4K 5193
2018
Q3
$4K Hold
110
﹤0.01% 5514
2018
Q2
$5K Hold
110
﹤0.01% 5580
2018
Q1
$7K Hold
110
﹤0.01% 5777
2017
Q4
$9K Sell
110
-5,000
-98% -$403K ﹤0.01% 6213
2017
Q3
$429K Sell
5,110
-13,200
-72% -$936K ﹤0.01% 5202
2017
Q2
$1.2M Buy
18,310
+7,570
+70% +$515K ﹤0.01% 4296
2017
Q1
$780K Buy
10,740
+9,200
+597% +$604K ﹤0.01% 4610
2016
Q4
$90K Buy
+1,540
New +$81.3K ﹤0.01% 6187

Other funds holding ADNT

Goldman Sachs's ADNT Position: Q1 2026 in Review

Goldman Sachs increased its Adient (ADNT) stake by 36% in Q1 2026, buying an estimated $13M and bringing the position to 2,213,710 shares worth $44.7M. The position accounts for 0.01% of the portfolio, ranked #1671.

Goldman Sachs first reported a position in ADNT in Q4 2016 and has held it in 38 quarters since. The position peaked at $112M in Q2 2021. 287 funds tracked by Wall St. Rank hold ADNT as of Q1 2026.

  • Goldman Sachs held 2,213,710 shares of Adient worth $44.7M as of Q1 2026.
  • Goldman Sachs bought 586,306 Adient shares in Q1 2026, an estimated $13M.
  • Adient made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1671 holding.
  • Goldman Sachs first reported a position in Adient in Q4 2016 and has held it in 38 quarters since.
  • Goldman Sachs's Adient position peaked at $112M in Q2 2021.
  • 287 funds tracked by Wall St. Rank held Adient as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.